科倫博泰生物-B(06990.HK):核心產品蘆康沙妥珠單抗(sac-TMT)於2024年美國臨牀腫瘤學會年會上公佈的研究成果
格隆匯5月24日丨科倫博泰生物-B(06990.HK)發佈公吿,公司將在於2024年5月31日至6月4日於美國芝加哥市舉行的2024年美國臨牀腫瘤學會(ASCO)年會上,於當地時間2024年6月2日早上9:45至11:15舉辦的臨牀科學研討會(摘要#104;下一代抗體藥物偶聯物:變革在繼續)上公佈其抗TROP2 ADC蘆康沙妥珠單抗(sac-TMT)(前稱SKB264/ MK-2870)用於既往接受過治療的局部復發或轉移性三陰性乳腺癌(TNBC)患者的3期研究(OptiTROP-Breast01)結果。此外,於當地時間2024年5月31日下午2:45 至5:45的口頭報吿環節(摘要#8502;肺癌 - 轉移性非小細胞),公司將展示蘆康沙妥珠單抗(sac-TMT)聯合KL-A167(抗PD-L1單抗)用於一線治療晚期非小細胞肺癌(NSCLC)患者的2期研究(OptiTROP-Lung01)結果。蘆康沙妥珠單抗(sacTMT)在臨牀階段為公司與默沙東(美國新澤西州羅威市默克公司的商號)聯合開發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.